PhlemingoPharma
Guest
PhlemingoPharma
Guest
Thank you dear leader and dear father for taking the company to new heights, and thank you to the Board of Directors for empowering our dear leader and dear father to bless this company.
Shire (last 5 years): +56.80%
Nasdaq Biotechnology ETF(last 5 years): +128%
S&P 500 SPDR ETF(last 5 years): +84.33%
AbbVie Inc: +159.14%
Glassdoor ratings: 2.7 overall, 26% approve CEO, 26% positive business outlook.
2020 Goal Tracking: "Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs. ... The London-listed pharmaceutical group said total revenue would now reach $17-18 billion by 2020, dropping the goal set two years ago when it acquired hemophilia specialist Baxalta."
Shire (last 5 years): +56.80%
Nasdaq Biotechnology ETF(last 5 years): +128%
S&P 500 SPDR ETF(last 5 years): +84.33%
AbbVie Inc: +159.14%
Glassdoor ratings: 2.7 overall, 26% approve CEO, 26% positive business outlook.
2020 Goal Tracking: "Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs. ... The London-listed pharmaceutical group said total revenue would now reach $17-18 billion by 2020, dropping the goal set two years ago when it acquired hemophilia specialist Baxalta."